Trial Profile
Oral vinorelbine (NVBo) in Asian Advanced Breast Cancer (ABC) and Non Small Cell Lung Cancer (NSCLC) patients (pts): Pharmacokinetics (PK) coupled with efficacy and safety as first line treatment - A Chinese experience
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2016
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary)
- Indications Breast cancer; Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 21 Jan 2016 New trial record